Cargando…
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients
A phase II study was undertaken to determine the safety of combining flutamide with gemcitabine, with response rate being the primary end point. Twenty-seven patients with histologically proven, previously untreated, unresectable pancreatic adenocarcinoma received gemcitabine, 1 g m(−2) intravenousl...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2002
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364255/ https://www.ncbi.nlm.nih.gov/pubmed/12232752 http://dx.doi.org/10.1038/sj.bjc.6600523 |